Improving Nutrition for Babies Born by Caesarean Section

NCT ID: NCT07162025

Last Updated: 2025-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-30

Study Completion Date

2028-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ambition of the project is to help with the primal colonisation of babies born by caesarean section and to improve the lipid composition of an infant formula, in order to reduce the short- and long-term health problems associated with caesarean births. This population, which represents around 20% of babies born in France, has not yet received any specific care to date.

The study aims to develop an optimized infant formula. It includes: (1) isolation of probiotics from breast milk from nursing mothers and stool samples from their babies born vaginally, (2) formulation of an improved milk enriched with physiological lipids and selected probiotics, and (3) preclinical evaluation of its beneficial effects in a cesarean birth model.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The perinatal period represents a critical window during which the establishment of the infant gut microbiota plays a central role in host physiology and immune system development. Cesarean delivery is associated with altered vertical transmission of maternal microbiota, leading to dysregulated host-microbiota interactions and impaired homeostasis. Epidemiological evidence indicates that disturbances in early-life colonization are linked to an increased risk of developing various non-communicable diseases later in life.

Modern obstetric practices, while highly effective in reducing birth complications, have resulted in a high prevalence of cesarean deliveries. Several strategies have been explored to restore the microbiota of cesarean-born infants, including maternal vaginal or fecal microbiota transfer, but these approaches raise significant safety concerns. Breastfeeding has been shown to partially restore the gut microbiota of cesarean-born infants; however, breastfeeding rates are lower after cesarean section than after vaginal delivery, largely due to postnatal complications that interfere with breastfeeding initiation. Although specific infant formulas already exist for certain populations, none are currently designed to address the impaired primary colonization observed in cesarean-born infants.

The SPECIFI-C project has been designed to fill this gap by developing an innovative infant formula tailored to the specific needs of this population. The strategy focuses on two main components: (i) optimization of the microbiological fraction through supplementation with beneficial microorganisms isolated from human breast milk and infant feces, and (ii) optimization of the lipid fraction by incorporating bioactive lipids such as docosahexaenoic acid (DHA) and alkylglycerols, which are naturally present in breast milk but absent from current formulas.

The ultimate objective is to provide a safe and effective nutritional intervention that promotes healthy gut colonization and supports immune and physiological development in cesarean-born infants. By targeting a population that represents approximately 20% of births in France, the project aims to contribute to more precise and personalized nutrition strategies, with the potential to reduce both short- and long-term health risks associated with cesarean delivery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breastfeeding Mothers of Legal Age Their Babies Under 6 Months Old Born Vaginally

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Breastfeeding mothers:

Aged 18 years and older Breastfeeding for less than 6 months Not having taken probiotics in the 6 months prior to sampling Not having taken antibiotics in the 6 months prior to sampling No chronic medical conditions Not undergoing chronic treatment No history of gestational diabetes Body mass index (BMI) below 25 at the start of pregnancy Having given their consent to participate in the study and to the collection of their baby's stool samples Not deprived of liberty or placed under guardianship


* Receiving medical supplementation other than conventional vitamins

Exclusion Criteria

Breastfeeding mothers:

* Under the age of 18
* Breastfeeding for 6 months or more
* Having been on antibiotic therapy in the 6 months prior to sampling
* Having taken probiotics in the 6 months prior to sampling
* Having a chronic illness
* Undergoing chronic treatment
* Who have developed gestational diabetes
* Who have a BMI greater than 25 at the start of pregnancy
* Who have given their consent to participate in the study (breast milk collection) but not to the collection of their baby's stool samples
* Who are deprived of their liberty or under guardianship.

Babies:

* Aged over 6 months
* Born by caesarean section
* Born before 37 weeks of pregnancy
* Not exclusively breastfed
* Having undergone intrapartum antibiotic treatment
* Taking medical supplements other than conventional vitamins
* Presenting with any type of pathology
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

INRAE

Jouy-en-Josas, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

REBECA MARTIN-ROSIQUE, PhD

Role: CONTACT

00 33 1 34 65 20 98

ELISE BOREZEE, PhD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

REBECA MARTIN ROSIQUE, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-A00676-43

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Family-Centered Cesarean Delivery
NCT02690077 COMPLETED NA
IC-CS Risk: Patient Outcomes
NCT06488092 ACTIVE_NOT_RECRUITING NA